당뇨병성 망막증 치료 시장 : 당뇨병성 망막증 유형별, 치료 유형별, 최종 사용자별, 국가별, 지역별-산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Diabetic retinopathy therapeutic market size was valued at USD 9,109.32 Million in 2023, expanding at a CAGR of 6.88% from 2024 to 2032.

Diabetic retinopathy is a serious eye condition stemming from complications related to diabetes mellitus and is a leading cause of blindness worldwide. The severity of diabetic retinopathy depends on several factors, including the type of diabetes, the duration of the disease, and how well blood sugar levels are managed. Early symptoms may be minimal or even absent, but as the condition progresses, individuals can experience blurred vision, fluctuating eyesight, and impaired color perception, potentially leading to blindness if not addressed.

Diabetic Retinopathy Therapeutic Market- Market Dynamics

Increasing prevalence of diabetes and diabetic retinopathy to propel market demand

The rising incidence of diabetes globally has led to a higher number of individuals developing diabetic retinopathy. According to Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people across all ages in the US were living with diabetic retinopathy in 2021.However, the complexity of treatment regimens and the potential side effects of therapies can discourage patients from adhering to their prescribed treatment plans. On the contrary, ongoing research and technological advancements in the management of diabetic retinopathy are expected to boost market growth. Furthermore, Increased awareness about the importance of regular eye examinations for diabetes patients presents an opportunity for growth in the diabetic retinopathy therapeutic market.

Diabetic Retinopathy Therapeutic Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.88% over the forecast period (2024-2032)

Based on diabetic retinopathy type segmentation, non-proliferative diabetic retinopathy was predicted to show maximum market share in the year 2023

Based on treatment type segmentation, anti-vascular endothelial growth factor (VGEF) drug was the leading segment in 2023

On the basis of region, The North America diabetic retinopathy therapeutic market was the leading revenue generator in 2023

Diabetic Retinopathy Therapeutic Market- Segmentation Analysis:

The Global Diabetic Retinopathy Therapeutic Market is segmented on the basis of Diabetic Retinopathy Type, Treatment Type, End user, and Region.

The market is divided into two categories based on diabetic retinopathy type: proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy sector dominates the market. This is mainly due to its higher prevalence among diabetic patients and the increasing awareness and availability of early detection and treatment options.

The market is divided into four categories based on end user: ophthalmic centers, hospitals, ambulatory surgery centers, and others. The hospitals sector dominates the market and is likely to maintain its dominance during the forecast period. This dominance is primarily driven by hospitals' ability to provide comprehensive care, including advanced diagnostic tools and surgical interventions, which are crucial for managing diabetic retinopathy effectively.

Diabetic Retinopathy Therapeutic Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Diabetic Retinopathy Therapeutic Market- Competitive Landscape:

The increasing prevalence of diabetic retinopathy is driving a competitive landscape characterized by innovative treatment strategies and a focus on comprehensive patient care. Companies are leveraging advanced technologies, such as telemedicine and digital health solutions, to enhance patient engagement and improve access to care. Additionally, many organizations are prioritizing research and development to introduce novel therapies that target various stages of diabetic retinopathy, thereby addressing unmet medical needs. Collaboration and partnerships with healthcare providers and research institutions are also common strategies, enabling companies to expand their market reach and improve treatment outcomes.

Recent Developments:

In April 2024, Ocular Therapeutix, Inc. announced promising topline results from its Phase 1 HELIOS study, which investigated AXPAXLI against a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). The study's positive findings highlight Ocular's commitment to developing innovative therapies for conditions like wet age-related macular degeneration and diabetic retinopathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• F. Hoffmann-La Roche Ltd.
• Abbott
• Alimera Sciences
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Oxurion NV
• ABBVIE INC.
• Sirnaomics
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Genentech, Inc.
• Kowa Company Ltd.
• Aurobindo Pharma
• Bausch Health Companies Inc.
• Accord Healthcare
• Regeneron Pharmaceuticals Inc.
• Lumenis Be Ltd.
• Glycadia, Inc.
• Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY DIABETIC RETINOPATHY TYPE- MARKET ANALYSIS, 2019 - 2032

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

• Laser Surgery
• Anti-vascular Endothelial Growth Factor (VEGF) Drug
• Intraocular Steroid Injection
• Vitrectomy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

• Ophthalmic Centers
• Hospitals
• Ambulatory Surgery Centers
• Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Diabetic Retinopathy Therapeutic Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Diabetic Retinopathy Therapeutic Market Snippet by Diabetic Retinopathy Type
  • 2.1.2. Diabetic Retinopathy Therapeutic Market Snippet by Treatment Type
  • 2.1.3. Diabetic Retinopathy Therapeutic Market Snippet by End User
  • 2.1.4. Diabetic Retinopathy Therapeutic Market Snippet by Country
  • 2.1.5. Diabetic Retinopathy Therapeutic Market Snippet by Region
• 2.2. Competitive Insights

3. Diabetic Retinopathy Therapeutic Key Market Trends

• 3.1. Diabetic Retinopathy Therapeutic Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Diabetic Retinopathy Therapeutic Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Diabetic Retinopathy Therapeutic Market Opportunities
• 3.4. Diabetic Retinopathy Therapeutic Market Future Trends

4. Diabetic Retinopathy Therapeutic Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Diabetic Retinopathy Therapeutic Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Diabetic Retinopathy Therapeutic Market Landscape

• 6.1. Diabetic Retinopathy Therapeutic Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Diabetic Retinopathy Therapeutic Market - By Diabetic Retinopathy Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Diabetic Retinopathy Type, 2023 & 2032 (%)
  • 7.1.2. Proliferative Diabetic Retinopathy
  • 7.1.3. Non-proliferative Diabetic Retinopathy

8. Diabetic Retinopathy Therapeutic Market - By Treatment Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
  • 8.1.2. Laser Surgery
  • 8.1.3. Anti-vascular Endothelial Growth Factor (VEGF) Drug
  • 8.1.4. Intraocular Steroid Injection
  • 8.1.5. Vitrectomy

9. Diabetic Retinopathy Therapeutic Market - By End User

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
  • 9.1.2. Ophthalmic Centers
  • 9.1.3. Hospitals
  • 9.1.4. Ambulatory Surgery Centers
  • 9.1.5. Others

10. Diabetic Retinopathy Therapeutic Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Diabetic Retinopathy Therapeutic Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Retinopathy Therapeutic Industry

• 11.1. Competitive Dashboard
  • 11.1.1. Competitive Benchmarking
  • 11.1.2. Competitive Positioning
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd.
  • 11.2.2. Abbott
  • 11.2.3. Alimera Sciences
  • 11.2.4. Novartis AG
  • 11.2.5. Pfizer Inc.
  • 11.2.6. Regeneron Pharmaceuticals, Inc.
  • 11.2.7. Bayer AG
  • 11.2.8. Oxurion NV
  • 11.2.9. ABBVIE INC.
  • 11.2.10. Sirnaomics
  • 11.2.11. Ampio Pharmaceuticals Inc.
  • 11.2.12. BCNPeptides
  • 11.2.13. Genentech, Inc.
  • 11.2.14. Kowa Company Ltd.
  • 11.2.15. Aurobindo Pharma
  • 11.2.16. Bausch Health Companies Inc.
  • 11.2.17. Accord Healthcare
  • 11.2.18. Regeneron Pharmaceuticals Inc.
  • 11.2.19. Lumenis Be Ltd.
  • 11.2.20. Glycadia, Inc.
  • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us